Outcome after Radiotherapy for Vestibular Schwannomas – Differences in Tumor Control, Symptoms and Quality of Life after Radiotherapy with Photon versus Proton Therapy.
13/04/2022
/
Publications
/
Hypofractionation
Quality of life
Based on the data of 261 patients with VS treated with stereotactic radiosurgery/hypofractionated stereotactic radiotherapy (SRS/HFSRT), this study reported at...
Proton therapy for adult craniopharyngioma: Experience of a single institution in 91 consecutive patients.
14/04/2023
/
Publications
/
Toxicity
This study presented the treatment results of 91 patients with craniopharyngioma received proton therapy after tumor resection (88 patients, 97%), as an...
Proton Radiotherapy for Skull-Base Malignancies: Imaging Considerations of Radiotherapy and Complications.
14/08/2023
/
Publications
/
Imaging System
Toxicity
This article summarized data of PRT for benign and malignant skull-base tumors including pituitary adenomas, craniopharyngiomas, benign meningiomas, vestibular...
Analysis of safety and efficacy of proton radiotherapy for IDH-mutated glioma WHO grade 2 and 3.
14/05/2023
/
Publications
This study reported outcomes of 194 patients diagnosed with IDH-mutated WHO grade 2 (n = 128) and WHO grade 3 (n = 66) glioma treated with proton radiation...
Proton radiotherapy in the treatment of IDH-mutant diffuse gliomas: an early experience from shanghai proton and heavy ion center.
14/05/2023
/
Publications
/
Proton therapy center
This study presented results of 52 patients with IDH-mutant diffuse gliomas treated with proton radiation. Tumor classified by WHO grade 2, 3 and 4 were 22, 25...
Comparison of the Effectiveness of Radiotherapy with 3D-CRT, IMRT, VMAT and PT for Newly Diagnosed Glioblastoma: A Bayesian Network Meta-Analysis.
14/12/2023
/
Publications
/
IMRT
VMAT
Based on six original studies including 816 glioblastoma multiforme patients, this comprehensive synthesis of data performed by a Bayesian network meta-analysis...
Vision loss following high-dose proton-based radiotherapy for skull-base chordoma and chondrosarcoma
14/05/2021
/
Publications
/
Dosimetry
This study included148 chordoma and chondrosarcoma patients and 283 individual eyes with functional vision at baseline who received a minimum 30GyRBE to 0.1cm3...
Particle Radiotherapy for Skull Base Chondrosarcoma: A Clinical Series from Italian National Center for Oncological Hadrontherapy.
14/09/2021
/
Publications
/
Toxicity
This study reported outcomes of 48 patients with skull base chondrosarcoma who underwent particle therapy (67% PT, 33% CIRT). With a median follow-up of 38...
Definitive high-dose, proton-based radiation for unresected mobile spine and sacral chordomas.
14/06/2022
/
Publications
/
Survival
Dosimetry
Sixty-seven patients with unresected spinal chordomas treated with PBT were evaluated. With a median follow-up of 56.2 months, 5- and 8-year OS were 83.5 % and...
Proton or Carbon Ion Therapy for Skull Base Chordoma: Rationale and First Analysis of a Mono-Institutional Experience.
14/03/2023
/
Publications
/
Toxicity
This study reported clinical outcomes of 44 patients treated with proton (89%) or carbon ion therapy (11%). At a median follow-up of 34.3 months, 2-, and 3-year...
Cookies policy
If you continue browsing this website, you agree to the use of cookies in order to provide you with services and offers tailored to your own interests.
Manage your cookie preferences
Respect for your privacy is still a priority for us at IBA.
Functional cookies ensure that the website runs smoothly. They cannot be turned off. By setting your preferences, you can turn the use of these cookies on and off on our website, although these settings will only be valid on the device you are currently using.